

10630355  
01-21-04

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number  
**WO 01/49357 A2**

- (51) International Patent Classification<sup>7</sup>: **A61M 25/10**
- (21) International Application Number: **PCT/US00/34600**
- (22) International Filing Date:  
18 December 2000 (18.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/475,727 30 December 1999 (30.12.1999) US
- (71) Applicant: **ADVANCED CARDIOVASCULAR SYSTEMS, INC.** [US/US]; 3200 Lakeside Drive, Santa Clara, CA 95052-8167 (US).
- (72) Inventors: **RAY, Pinaki**; 4747 Mendocino Terrace, Fremont, CA 94555 (US). **BHAT, Vinayak, D.**; 659 W. Hornestead Road #3, Sunnyvale, CA 94087 (US). **MIRZAEI, Daryush**; 629 Ashbourne Drive, Sunnyvale, CA 94087 (US).
- (74) Agents: **KERRIGAN, Cameron et al.**; Squire, Sanders & Dempsey L.L.P., 600 Hansen Way, Palo Alto, CA 94304-1043 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A SUBSTANCE DELIVERY APPARATUS AND A METHOD OF DELIVERING A THERAPEUTIC SUBSTANCE TO AN ANATOMICAL PASSAGEWAY



(57) Abstract: A catheter assembly is provided having a balloon disposed at the distal end thereof. The balloon is capable of being inflated to selectively dilate from a collapsed configuration to an expanded configuration. The balloon is also capable of being deflated after inflation to return to the collapsed configuration or a deflated profile. A syringe assembly is in fluid communication with a delivery lumen of the catheter assembly for allowing a therapeutic substance to be injected into a tissue of a passageway. The syringe assembly includes a portion capable of pivoting from a first position towards a second position when the balloon is being inflated from the collapsed configuration to the expanded configuration. The portion of the syringe assembly is also capable of pivoting from the second position back towards the first position when the balloon is being deflated. The balloon can be made from a porous membrane to allow a therapeutic substance that is supplied into the balloon to be discharged out from the porous membrane.

WO 01/49357 A2

# **A SUBSTANCE DELIVERY APPARATUS AND A METHOD OF DELIVERING A THERAPEUTIC SUBSTANCE TO AN ANATOMICAL PASSAGEWAY**

## **BACKGROUND OF THE INVENTION**

### **5 Field of the Invention**

The present invention pertains generally to a medical device useful for delivering a substance to a biological passageway. More specifically, the present invention pertains to a catheter device having a syringe assembly useful for delivering a therapeutic substance to a passageway, such as a blood vessel.

### **10 Description of the Related Art**

Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary  
15 vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress the atherosclerotic plaque of the lesion against the inner wall of the artery to dilate the lumen. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.

20 Restenosis of the artery commonly develops over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. Restenosis is thought to involve the body's natural healing process. Angioplasty or other vascular procedures injure the vessel walls, removing the vascular endothelium, disturbing the tunica intima, and causing the death of  
25 medial smooth muscle cells. Excessive neointimal tissue formation, characterized by smooth muscle cell migration and proliferation to the intima, follows the injury. Proliferation and migration of smooth muscle cells (SMC) from the media layer to the intima cause an excessive production of extra cellular matrices (ECM), which is believed to be one of the leading contributors to the

development of restenosis. The extensive thickening of the tissues narrows the lumen of the blood vessel, constricting or blocking blood flow through the vessel.

To reduce the chance of the development of restenosis, therapeutic substances are administered to the treatment site. For example, anticoagulant and antiplatelet agents are commonly used to inhibit the development of restenosis. In order to provide an efficacious concentration to the target site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery, thus, produces fewer side effects and achieves more effective results.

One commonly applied technique for the local delivery of a therapeutic substance is through the use of a medicated, implantable prosthesis, one example of which includes a stent. A stent coated with a polymeric carrier, which is impregnated with a therapeutic substance, can be deployed at a selected site of treatment. The polymeric carrier allows for a sustained delivery of the therapeutic substance. A disadvantage associated with the use of medicated stents is that the quantity of the substance that can be impregnated in the polymeric carrier is limited. In order to increase the capacity of the polymeric carrier, the amount of polymeric material employed, and in effect the thickness of the coating, must be increased to accommodate the quantity of the substance used. An increase in the profile of the coating significantly limits the applications for which the stents can be used.

Another disadvantage associated with the use of medicated stents is that the polymeric carrier is only capable of applying the therapeutic substance to the inner surface of the tunica intima layer of the vessel. The polymeric carrier is incapable of significantly introducing a therapeutic substance to the tunica adventitia or the tunica media layers of the vessel. Accordingly, it is desirable to provide a substance delivery apparatus which is capable of applying any desired amount of therapeutic substances to the tunica adventitia and media layers to inhibit migration of SMC and the development of ECM.

Another commonly applied technique for the local delivery of a therapeutic substance is through the use of porous balloons attached to a distal end of a catheter assembly. The expansion of the balloon, which in effect results in the dilation of the occluded region, is accomplished by injecting a therapeutic substance into the balloon. The use of a therapeutic substance as an expansion fluid additionally functions as a medicament for the diseased region, as the therapeutic substance is discharged from the porous balloon during and subsequent to the expansion therapy. A shortcoming associated with this procedure is that the therapeutic substance is contiguously carried off in the patient's blood stream as it is being discharged from the balloon, which results in an ineffective treatment of the target site and adverse exposure of the substance to healthy tissues. Accordingly, it is desirable to provide a substance delivery apparatus that is capable of applying a therapeutic substance to the diseased region without significant loss of the substance caused by the downstream flow of blood.

## 15 SUMMARY OF THE INVENTION

A catheter assembly is provided having a balloon disposed at the distal end thereof. The balloon is capable of being inflated to selectively dilate from a collapsed configuration to an expanded configuration. The balloon is also capable of being deflated after inflation to return to the collapsed configuration or a deflated profile. A syringe assembly is in fluid communication with a delivery lumen of the catheter assembly for allowing a therapeutic substance to be injected into a tissue of a lumen. The syringe assembly includes a portion capable of pivoting from a first position towards a second position when the balloon is being inflated from the collapsed configuration to the expanded configuration. The portion of the syringe assembly is capable of pivoting from the second position back towards the first position when the balloon is being deflated.

In accordance with one embodiment, the balloon is made from a porous membrane. A therapeutic substance can be used as an inflation fluid for the porous balloon. The pores allow the therapeutic substances to be discharged out from the balloon for the local treatment of the tissues. The therapeutic substance supplied into and discharged out from the balloon can be the same as or different from the therapeutic substance administered by the syringe assembly.

In another embodiment, the delivery apparatus can include any suitable number of pivotally activated syringe assemblies. Each of the syringe assemblies can communicate with a common delivery lumen of the catheter assembly so that each of the syringe assemblies is capable of injecting the same therapeutic  
5 substance or the same combination of therapeutic substances. Alternatively, each of the syringe assemblies can be linked to an independently operated delivery lumen, allowing each of the syringe assemblies to be capable of delivering a different substance or a different combination of substances.

A method is provided for administering a therapeutic substance using the  
10 embodiments of the above described catheter assembly. The catheter assembly is inserted in a biological passageway of a subject and the syringe assembly is positioned at a desired area of treatment. The syringe assembly is pivotally rotated to cause a needle of the syringe assembly to penetrate into a wall of the desired area of treatment. A therapeutic substance is supplied through the delivery lumen  
15 of the catheter assembly to administer the therapeutic substance to the desired area of treatment.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a partial cross-sectional view of one embodiment of a substance delivery apparatus of the present invention in the form of a catheter assembly having a balloon in a collapsed configuration and a syringe assembly is a rested position;

Figure 2 is a partial cross-sectional view of the delivery apparatus of Figure 1, illustrating the balloon in an expanded configuration and the syringe assembly pivotally rotated to a delivery position;

Figure 3 is a partial cross-sectional view of another embodiment of a substance delivery apparatus of the present invention in the form of a catheter assembly having a balloon in an expanded configuration and a syringe assembly pivotally rotated to a delivery position;

Figure 4 is a partial cross-sectional view of another embodiment of a substance delivery apparatus of the present invention in the form of a catheter assembly having a balloon in an expanded configuration and a syringe assembly pivotally rotated to a delivery position, the delivery apparatus includes an iontophoresis element for providing a transport force for the substance;

Figures 5 and 6 are illustrations of acts performed for delivering a therapeutic substance to the tissues of a blood vessel using one embodiment of the substance delivery apparatus of the present invention;

Figure 7 is a cross-sectional view of a mammalian artery, illustrating each layer of the wall; and

Figure 8 is a partial prospective view of a mammalian vessel, illustrating the vasa vasorum networked along the tunica adventitia layer of the vessel.

25

## DETAILED DESCRIPTION OF THE EMBODIMENTS

### APPARATUS

Referring now to the drawings, wherein similar parts are identified by like reference numerals, Figures 1 and 2 illustrate a substance delivery apparatus in accordance with one embodiment of the invention. In general, the substance delivery apparatus provides a system for delivering a substance, such as a therapeutic substance or a combination of therapeutic substances, to or through a desired area of a passageway in order to treat a localized area of the passageway or to treat a localized area of tissue located adjacent to the passageway. The substance delivery apparatus includes a catheter assembly 10, which is intended to broadly include any medical device design for insertion into a body passageway to permit injection and/or withdrawal of fluids, to maintain the patency of the passageway, or for any other purpose. It is contemplated that the substance delivery apparatus has applicability for use with any biological passageway, including blood vessels, urinary tract, intestinal tract, kidney ducts, wind pipes, and the like.

Catheter assembly 10 is defined by an elongated catheter tube 12 having a proximal end (not illustrated) and distal end 14. Catheter assembly 10 can include a guidewire lumen 16 for allowing catheter assembly 10 to be feed over and maneuvered over a guidewire 18. A balloon 20 is incorporated at distal end 14 of catheter assembly 10 and is in fluid communication with an inflation lumen 22 of catheter assembly 10.

Balloon 20 has a pair of opposing ends 24 and 26 engaged to catheter tube 12 to define a balloon chamber 28. Balloon 20 is formed from a balloon wall or membrane 30 which is selectively inflatable to dilate from a collapsed configuration to a desired and controlled expanded configuration. Balloon 20 can be selectively inflated by supplying a fluid into inflation lumen 22 at a predetermined rate of pressure, for example 1-20 atm. Balloon wall 30 is selectively deflatable, after inflation, to return to the collapsed configuration or a deflated profile. Balloon wall 30 can be defined by three sections, a distal wall 32, a medial wall 34, and a proximal wall 36. In one embodiment, as illustrated in Figure 2, proximal wall 36 of balloon 20 is generally perpendicular to a

longitudinal axis  $x$  of balloon 20, i.e.,  $\Phi$  is equal to about  $90^\circ$ , when balloon 20 is in the expanded configuration. In an alternative embodiment, as illustrated in Figure 3, proximal wall 36 can taper from opposing end 26 at any suitable angle  $\Phi$ , typically between about  $45^\circ$  to less than about  $90^\circ$ , when balloon 20 is in the expanded configuration.

The three wall sections 32, 34, and 36 can be bound together by seams or be made out of a single seamless material. Balloon 20 can be made from any suitable material, including, but not limited to, polymers and copolymers of polyolefins, polyamides, polyesters and the like. The specific material employed must be mutually compatible with the fluids employed in conjunction with balloon 20 and must be able to stand the pressures that are developed within balloon chamber 28. Balloon wall 30 can have any suitable thickness so long as the thickness does not compromise properties that are critical for achieving optimum performance. The properties include high burst strength, low compliance, good flexibility, high resistance to fatigue, the ability to fold, the ability to cross and recross a desired region of treatment or an occluded region in a lumen, and low susceptibility to defect caused by handling. By way of example, and not limitation, the thickness can be in the range of about 10 microns to about 30 microns, the diameter of balloon 20 in the expanded configuration can be in the range of about 2 mm to about 10 mm, and the length can be in the range of about 3 mm to about 40 mm, the specific specifications depending on the procedure for which balloon 20 is to be used and the anatomy and size of the target lumen in which balloon 20 is to be inserted.

In accordance with another embodiment of the invention, balloon wall 30 can be made from a porous membrane. In one embodiment, the pores (not illustrated) are disposed on medial wall 34 segment of balloon wall 30 or any selected area thereof, while distal 32 and proximal 36 wall segments are impermeable. In another embodiment, pores can also be located on distal wall 32 and/or proximal wall 36 segments of balloon wall 30. The pores can have a wide range in size, for example from about  $10 \text{ \AA}$  to less than about  $5 \mu$  in diameter. The pore density can be in any suitable range, typically in the range of about  $10^2$  to about  $10^6$  pores per  $\text{cm}^3$ .



To inflate the porous membrane, a fluid, usefully a therapeutic substance solution, is supplied into inflation lumen 22 at a predetermined pressure, for example about 4 atm. During inflation, the pressure should not exceed about 20 atm so as to prevent significant leakage of the fluid from the pores. The specific  
5 pressure depends of factors such as the size of the pores, the thickness of balloon wall 30, the material from which balloon wall 30 is made, the type of substance employed, and the flow rate that is desired. Significant amount of leakage of the fluid during inflation is a drawback because the therapeutic substance will get carried off in the patient's blood stream which results in an ineffective treatment  
10 of the diseased region and exposure of the substance to healthy tissues. Porous balloon 20 can be used to deliver a substance to the tissues at a desired flow rate.

The flow rate of a substance is determined in units of ml/min and is dependent upon flow parameters such as pore density, pore size, viscosity of the composition, and applied pressure. As a general rule, flow parameters can be  
15 interrelated in the following manner: The flow rate is proportional to the pore density if all other flow parameters are constant; the flow rate is proportional to the diameter of the pore raised by the power of four; the flow rate is inversely proportional to the viscosity of the composition used; and the flow rate is proportional to the applied pressure.

Pore size of about 10 Å to about 5 μ reduces the velocity at which the fluid is capable of traveling through a given pore, as compared to balloons having larger pore sizes, to prevent "jetting effect" that have significantly hindered the effectiveness of balloons having the larger pore sizes. "Jetting effect" is the  
20 velocity of liquid through a pore of a selected size at which trauma to the tissues occurs. The flow rate of delivery can be increased without increasing the velocity of the fluid through the pores. The flow rate of a fluid can be increased by increasing the pore density, which will provide the desired effect and delivery rate without increasing the fluid velocity.

The delivery apparatus includes a syringe assembly 38 for injecting a  
30 therapeutic substance into a tissue of a biological passageway. Syringe assembly 38 includes a hollow barrel 40 having a distal section 42 and a proximal section 44. Barrel 40 can be made from any suitable material such as polymers and

copolymers of polyamides, polyolefins, polyurethanes, and alike. A hollow needle 46, for penetrating into a tissue of a biological passageway, is in fluid communication with distal section 42 of barrel 40. The portion of needle 46 protruding from barrel 40 can be of any predetermined length  $l$ , the specific length  $l$  dependent upon the desired depth of calibrated penetration and the procedure for which syringe assembly 38 is to be used. Usefully, length  $l$  can be from about 250 microns to about 1 mm. Proximal section 44 of barrel 40 is in fluid communication with a delivery lumen 48. Distal section 42 of barrel 40 is capable of pivotally rotating about an elbow 50 with respect to proximal section 44. Distal section 42 of barrel 40 is in communication with proximal wall 36 of balloon 20, and accordingly, needle 46 is capable of pivoting about elbow 50 in response to the expansion and retraction of balloon 20. In the collapsed configuration of balloon 20, as illustrated in Figure 1, needle 46 of syringe assembly 38 is in a rested position, or in another words a longitudinal axis  $y$  of needle 46 is generally parallel to longitudinal axis  $x$  of balloon 20. The dilation of balloon 20 pivots needle 46 of syringe assembly 38 towards a selected delivery position, causing needle 46 to penetrate into a lumen wall. The extent of the rotation of distal section 42 is dependent upon the degree  $\Phi$  at which proximal wall 36 of balloon 20 tapers from end 26 when balloon 20 is in the expanded configuration. In one embodiment, proximal wall 36 tapers at about  $90^\circ$  from end 26, causing longitudinal axis  $y$  of needle 46, at the delivery position, to be generally perpendicular to longitudinal axis  $x$  of balloon 20 when balloon 20 is in the expanded configuration. In an alternative embodiment, as illustrated in Figure 3, longitudinal axis  $y$  of needle 46, at the delivery position, can be at any suitable angle  $\Phi$ , typically between about  $45^\circ$  to less than  $90^\circ$ .

In one embodiment, the delivery apparatus can include any suitable number of pivotally activated syringe assemblies 38, disposed about the periphery of balloon 20 and in communication with proximal wall 36. Each of syringe assemblies 38 can communicate with a respective, designated delivery lumen 48, two of which are illustrated as lumens 48a and 48b in Figures 1 and 2. The designated delivery lumens, e.g., delivery lumens 48a and 48b, can be in fluid communication with one another and/or in fluid communication with a common

source of supply of a therapeutic substance. Each of syringe assemblies 38 is, therefore, capable of injecting the same therapeutic substance or the same combination of therapeutic substances.

5 In an alternative embodiment, each of the designated delivery lumens, for example illustrative lumens 48a and 48b, are not in fluid communication with one another. The designated lumens 48a and 48b allow each of syringe assemblies 38 to be in fluid communication with a different source of supply of a therapeutic substance. Accordingly, each of syringe assemblies 38 will be capable of  
10 delivering a different therapeutic substance or different combinations of substances.

In one embodiment, as illustrated by Figure 4, iontophoresis technology, as is understood by one of ordinary skill in the art, can be used to drive ionic agents or drag nonionic agents that are in an ionic solution. In order for iontophoresis techniques to be utilized, the substance to be delivered should have an ionic nature  
15 or be bound to other ionic molecules. Iontophoresis can facilitate both transport of a substance across the porous membrane of balloon 20 and enhance tissue penetration of the substance. Referring to Figure 4, a first electrode 60 can be located within balloon 20 and is connected to a power supply 62 by a first lead 64. A second electrode 66 can be located either on the surface of or within the  
20 subject's body and is connected to power supply 62 by a second lead 68. The power supply provides an electric signal between first and second electrodes 60 and 66. The signal can be direct or have a particular wave form. Examples of possible wave forms include a rectangular wave having a frequency of about 10 Hz or greater. Additionally, a series of waves can be intermittently passed  
25 between first and second electrodes 60 and 66 during the process of delivering the substance.

In another embodiment, ultrasonic or high frequency sound waves can be used to transport a substance through the porous membrane and into the surrounding tissue. Phonophoresis or sonophoresis has several advantages over  
30 iontophoresis, including the ability to achieve greater penetration into internal tissues of the vessel wall. Phonophoresis is also not limited to delivering only ionically charged forms of the substance.

In addition to delivering a substance, ultrasound is advantageous because it can increase tissue temperature and capillary and cellular permeability. These results can enhance intra-tissue transport of a substance, enhance cellular uptake, and cause vasodilation/relaxation, which may be beneficial in vascular applications. As is understood by one of ordinary skill in the art, an ultrasonic piezoelectric transducer (not illustrated) such as barium titanate, lead zirconate titanate, or the like, can be disposed within balloon 20 and is connect to a power supply through catheter tube 12. As a general rule, the diffusion rate of substances delivered by phonophoresis depends on the type of substances and the intensity and frequency of the ultrasonic field. Phonophoretic delivery techniques employ various frequencies of sonic waves, e.g., about 1 MHz or less.

#### METHOD OF USE

An application of the various embodiments of the present invention will be generally described by way of example with reference to the treatment of a blood vessel having an occlusion cause by restenosis. One of ordinary skill in the art should realize that the various embodiments of the present invention could be used in a variety of other medical applications.

Referring to Figures 5 and 6, catheter assembly 10, having balloon 20 and syringe assembly 38, is advanced along guidewire 18 to a desired position in a vessel 70 so that balloon 20 overlays at least a portion of a stenotic lesion *s*. Balloon 20 can have either a porous or a nonporous membrane 30. Balloon 20 is inflated by introducing an inflation fluid into chamber 28 via inflation lumen 22. With a porous balloon 20, the inflation fluid can be a therapeutic substance or a combination of therapeutic substances. When balloon 20 is dilating to the expanded configuration, distal section 42 of syringe assembly 38 rotatably pivots outwardly about elbow 50, causing needle 46 to penetrate into the tissues of vessel 70 at a calibrated depth.

Figure 7 illustrates a cross section of a wall of blood vessel 70. The walls are composed of three tunics: tunica intima 72 composed of squamous epithelium called endothelium 74 underlain by a subendothelial layer 76 of loose connective tissues; tunica media 78, separated from the tunica intima 72 by an internal elastic

lamina 80, is made from smooth muscle cells (SMC) and elastic fibers; and tunica adventitia 82, the outer most layer, consists chiefly of connective tissues with irregularly arranged elastic and collagenous fibers. Proliferation and migration of SMC from the tunica media 78 to the tunica intima 74 causes an excessive  
5 production of extra cellular matrices (ECM), which is believed to be one of the leading contributors to the development of restenosis. Usefully, needle 46 should be calibrated so that it is capable of penetrating into the tunica media 78 layer to inhibit proliferation and migration of SMC and the development of ECM.

A therapeutic substance or a combination of therapeutic substances can be  
10 administered to the adventitia layer 82 and/or the media layer 78 via needle 46 by introducing the substance(s) through delivery lumen 48 at a selected pressure. Virtually any type of useful therapeutic substance of any given molecular size and weight can be injected through needle 46. Therapeutic substances having a molecular weight of less than about 5000 daltons are capable of penetrating  
15 through the intima layer 72. Thus, balloon 20 having porous membrane 30 can be used to administer such substances to the outer layers of the vessel wall. Therapeutic substances that are incapable of penetrating through intima layer 72 can be supplied by porous balloon 20 to the adventitia layer 82 via the vasa vasorum.

20 Discharging of a therapeutic substance out from balloon 20 in an expanded configuration, having medial wall 34 compressed against the inner wall of blood vessel 70, causes the therapeutic substance to penetrate into the vasa vasorum of blood vessel 70. As best illustrated in Figure 8, the tunica adventitia layer 82 is infiltrated with a network of tiny blood vessels, shown by arrows 94, called vasa  
25 vasorum. These "vessels of the vessels" nourish the more external tissue of the blood vessels (the inner portion obtains its nutrients directly from blood in the lumen). Discharge of a therapeutic substance into the vasa vasorum 94 causes such substances to be supplied to the tunica adventitia layer 82 of blood vessels.

Therapeutic substances or agents can include, but are not limited to,  
30 antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antiproliferative, antibiotic, antioxidant, antiallergic substances, and combinations thereof. Examples of suitable antineoplastics

include paclitaxel and docetaxel. Examples of suitable antiplatelets, anticoagulants, antifibrins, and antithrombins include sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E-3B® (an antiplatelet drug from Centocore). Examples of suitable antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mutamycin. Examples of suitable cytostatic or antiproliferative agents include angiopeptin (a somatostatin analogue from Ibsen), angiotensin converting enzyme inhibitors such as Captopril® (available from Squibb), Cilazapril® (available from Hofman-LaRoche), or Lisinopril® (available from Merck); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonist, Lovastatin® (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available from Glaxo), Seramin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent includes Permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, dexamethasone, and growth factors such as FGF, PDGF, and VEGF. While the foregoing therapeutic substances or agents are well known for their preventative and treatment properties, the substances or agents are provided by way of example and are not meant to be limiting. Other therapeutic substances which are currently available or that may be developed are equally applicable for use with the present invention. The treatment of patients using the above-mentioned medicines is well known to those of ordinary skill in the art.

The catheter which includes syringe assembly 38 may be the same balloon catheter employed to dilate the vessel, thus combining the dual function of therapeutic substance delivery and dilation of the lesion into one catheter.

Alternatively, a vessel may be dilated first with a catheter designed specifically for dilation, followed by insertion of a catheter having syringe assembly 38 for therapeutic substance delivery.

5 While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

## WHAT IS CLAIMED IS:

1. A substance delivery apparatus, comprising:
  - (a) a needle capable of penetrating into tissues of a subject for administering a substance to said subject; and
  - 5 (b) a hollow body in fluid communication with said needle, said hollow body being defined by a first section and a second section, wherein said first section is capable of pivotally rotating with respect to said second section.
- 10 2. The substance delivery apparatus of Claim 1, additionally comprising a catheter assembly and a balloon disposed at a distal end of said catheter assembly, wherein said first section of said hollow body pivotally rotates with respect to said second section in response to inflation of said balloon.
3. The substance delivery apparatus of Claim 2, wherein said balloon is made from a porous membrane.
- 15 4. The substance delivery apparatus of Claim 2, additionally comprising a transport element operably supported by said catheter assembly, said transport element having a first electrode element, a second electrode element, and a power supply electrically communicating with said first and second electrode elements, wherein said first electrode element is positioned within said balloon.
- 20 5. The substance delivery apparatus of Claim 2, additionally comprising a transport element operably supported by said catheter assembly, said transport element having an ultrasonic transducer.
6. A device for delivering a substance to a desired area of treatment, comprising:
  - 25 (a) a catheter assembly having a distal end and a proximal end;
  - (b) a balloon disposed at said distal end of said catheter assembly, wherein said balloon is capable of being inflated to selectively dilate from



a collapsed configuration to an expanded configuration and said balloon is capable of being deflated after inflation to retract to a deflated profile; and

(c) a first syringe assembly in fluid communication with said catheter assembly for allowing a first therapeutic substance to be injected into a tissue of a lumen, wherein said first syringe assembly includes a portion capable of pivoting from a first position towards a second position in response to said balloon being inflated from said collapsed configuration to said expanded configuration, and wherein said portion of said first syringe assembly is capable of pivoting from said second position back towards said first position in response to said balloon being deflated.

7. The device of Claim 6, wherein said first syringe assembly is configured to penetrate into the tunica media layer of a blood vessel for administering said first therapeutic substance to a region of the tunica media layer of said blood vessel.

8. The device of Claim 6, wherein said balloon is made from a membrane having a plurality of pores for allowing a second therapeutic substance supplied into said balloon to be discharge out from said pores.

9. The device of Claim 8, wherein said second therapeutic substance is different than said first therapeutic substance.

10. The device of Claim 8, wherein said second therapeutic substance is the same as said first therapeutic substance.

11. The device of Claim 6, wherein when said balloon is in said collapsed configuration, a longitudinal axis of said portion of said first syringe assembly is generally parallel to a longitudinal axis of said balloon and when said balloon is in said expanded configuration, said longitudinal axis of said portion of said first syringe assembly is about 45° to about 90° from said longitudinal axis of said balloon.

12. The device of Claim 6, additionally comprising a second syringe assembly in fluid communication with said catheter assembly for allowing a

second therapeutic substance to be injected into a tissue of said lumen, said second therapeutic substance being different than said first therapeutic substance, wherein said second syringe assembly comprises a portion capable of pivoting from a first position towards a second position in response to said balloon being inflated from  
5 said collapsed configuration to said expanded configuration, and wherein said portion of said second syringe assembly is capable of pivoting from said second position back towards said first position in response to said balloon being deflated.

13. The device of Claim 6, additionally comprising a transport element operably connected to said catheter assembly, said transport element having a first  
10 electrode element, a second electrode element, and a power supply electrically communicating with said first and second electrode elements, wherein said first electrode element is positioned within said balloon.

14. The device of Claim 6, additionally comprising a transport element operably connected to said catheter assembly, said transport element having an  
15 ultrasonic transducer.

15. A method for administering a therapeutic substance, comprising the acts of:

- (a) providing a catheter device having a first syringe assembly in fluid communication with a first delivery lumen of said catheter device;
- 20 (b) inserting said catheter device in a biological passageway of a subject;
- (c) position said syringe assembly at a desired area of treatment;
- (d) causing a portion of said first syringe assembly to pivotally rotate for penetrating a needle of said first syringe assembly into a wall of  
25 said desired area of treatment; and
- (e) supplying a first therapeutic substance through said first delivery lumen of said catheter device to administer said first therapeutic substance to said desired area of treatment.

16. The method of Claim 15, wherein said catheter device additionally comprises a balloon having a section communicating with said portion of said first syringe assembly, wherein said act (d) comprises inflating said balloon from a collapsed configuration to an expanded configuration to cause said portion of said first syringe assembly to pivotally rotate from a first position to a second position.

17. The method of Claim 15, wherein said catheter device additionally comprises a balloon made from a porous membrane, wherein the method additionally comprises the act of supplying a second therapeutic substance into said balloon to inflate said balloon from a collapsed configuration to an expanded configuration and to discharge said second therapeutic substance out from said porous membrane.

18. The method of Claim 17, wherein said first therapeutic substance is the same as said second therapeutic substance.

19. The method of Claim 17, wherein said first therapeutic substance is different than said second therapeutic substance.

20. The method of Claim 15, wherein said catheter device additionally comprises a second syringe assembly in fluid communication with a second delivery lumen of said catheter device, wherein the method additionally comprises the act of:

(a) causing a portion of said second syringe assembly to pivotally rotate for penetrating a needle of said second syringe assembly into said wall of said desired area of treatment; and

(b) supplying a second therapeutic substance through said second delivery lumen of said catheter device to administer said second therapeutic substance to said desired area of treatment, wherein said second therapeutic substance is different than said first therapeutic substance.

21. A medical assembly, comprising:

(a) a catheter assembly capable of being guided through anatomical passageways of a subject, said catheter assembly having a first lumen and a second lumen;

5 (b) a selectively inflatable member having outer ends engaged to a distal end of said catheter assembly, said member being in fluid communication said first lumen and said member being formed from a porous membrane which defines a therapeutic substance receiving and dispensing chamber bounded by said outer ends of said member, wherein a first therapeutic substance can be supplied into said first lumen to  
10 selectively inflate said member and to discharge said first therapeutic substance out from said chamber through said porous membrane; and

(c) a first syringe in fluid communication with said second lumen of said catheter assembly and capable of penetrating into a tissue of a passageway, wherein a user can supply a second therapeutic substance into  
15 said second lumen for injection of said second therapeutic substance out from said first syringe.

22. The medical assembly of Claim 21, wherein said first therapeutic substance is different than said second therapeutic substance.

23. The medical assembly of Claim 21, additionally comprising:

20 (a) a third lumen extending along at least a portion of said catheter assembly;

(b) a second syringe in fluid communication with said third lumen of said catheter assembly and capable of penetrating into a tissue of said passageway, wherein a user can supply a third therapeutic substance into  
25 said third lumen for injection of said third therapeutic substance out from said second syringe.

24. The medical assembly of Claim 23, wherein said third therapeutic substance is different than said second therapeutic substance.

25. The medical assembly of Claim 23, wherein said third therapeutic substance is different than said first and second therapeutic substances.




FIG. 1





FIG. 2




..



..





**FIG. 5**



**FIG. 6**



4/4

**FIG. 7****FIG. 8**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number  
**WO 01/49357 A3**

(51) International Patent Classification<sup>7</sup>: A61M 29/02. 5/32

(21) International Application Number: PCT/US00/34600

(22) International Filing Date:  
18 December 2000 (18.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/475,727 30 December 1999 (30.12.1999) US

(71) Applicant: ADVANCED CARDIOVASCULAR SYSTEMS, INC. [US/US]: 3200 Lakeside Drive, Santa Clara, CA 95052-8167 (US).

(72) Inventors: RAY, Pinaki: 4747 Mendocino Terrace, Fremont, CA 94555 (US). BHAT, Vinayak, D.: 659 W. Hornestead Road #3, Sunnyvale, CA 94087 (US). MIRZAEI, Daryush: 629 Ashbourne Drive, Sunnyvale, CA 94087 (US).

(74) Agents: KERRIGAN, Cameron et al.: Squire, Sanders & Dempsey L.L.P., 600 Hansen Way, Palo Alto, CA 94304-1043 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
6 December 2001

[Continued on next page]

(54) Title: A SUBSTANCE DELIVERY APPARATUS AND A METHOD OF DELIVERING A THERAPEUTIC SUBSTANCE INTO THE WALL OF AN ANATOMICAL PASSAGEWAY



(57) Abstract: A catheter assembly is provided having a balloon disposed at the distal end thereof. The balloon is capable of being inflated to selectively dilate from a collapsed configuration to an expanded configuration. The balloon is also capable of being deflated after inflation to return to the collapsed configuration or a deflated profile. A syringe assembly is in fluid communication with a delivery lumen of the catheter assembly for allowing a therapeutic substance to be injected into a tissue of a passageway. The syringe assembly includes a portion capable of pivoting from a first position towards a second position when the balloon is being inflated from the collapsed configuration to the expanded configuration. The portion of the syringe assembly is also capable of pivoting from the second position back towards the first position when the balloon is being deflated. The balloon can be made from a porous membrane to allow a therapeutic substance that is supplied into the balloon to be discharged out from the porous membrane.

WO 01/49357 A3



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34600

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61M29/02 A61M5/32

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 693 029 A (LEONHARDT ) 2 December 1997 (1997-12-02)  abstract; figures 1-5 ---	1,6,7, 9-12, 21-25
A	US 5 286 254 A (SHIMADA ET AL.) 15 February 1994 (1994-02-15) abstract; claims 1-11; figures 1,6 ---	1-6,8, 14,21
A	US 5 464 395 A (FAXON ET AL.) 7 November 1995 (1995-11-07) abstract; figures 12,13 -----	21-25

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 July 2001

Date of mailing of the international search report

17/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Michels, N

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/34600

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5693029 A	02-12-1997	AU 6338396 A EP 1083959 A WO 9702859 A	10-02-1997 21-03-2001 30-01-1997
US 5286254 A	15-02-1994	AU 3321293 A AU 3321793 A EP 0611311 A JP 7500523 T WO 9405361 A WO 9405369 A US 5498238 A US 5458568 A US 5499971 A US 5282785 A AT 123658 T AU 8074591 A DE 69110467 D DE 69110467 T EP 0533816 A WO 9119529 A US 5628730 A	29-03-1994 29-03-1994 24-08-1994 19-01-1995 17-03-1994 17-03-1994 12-03-1996 17-10-1995 19-03-1996 01-02-1994 15-06-1995 07-01-1992 20-07-1995 01-02-1996 31-03-1993 26-12-1991 13-05-1997
US 5464395 A	07-11-1995	WO 9526776 A	12-10-1995